Topic: MS

Update on treatment trials: teriflunomide, daclizumab and CombiRx

March 21, 2013  

Effect of NaCl on pathogenic Th17 cells

March 21, 2013  

Application to FDA for first-line natalizumab

March 13, 2013  

Vitamin D and MS: conflicting evidence of clinical benefit

February 27, 2013  

RIS: what are the risk factors for CIS/MS?

February 13, 2013  

The Year in (P)review – MS 2013 – Is the Injectable Era (almost) Over?

January 31, 2013  

RIS: what are the risk factors for CIS/MS?

December 26, 2012  

Neuroprotection: This is your brain on tea

December 5, 2012  

FDA delays review of alemtuzumab

November 7, 2012  

Aubade for Aubagio: FDA approves teriflunomide in RRMS

October 24, 2012